Genmab | GEN - Operating Profit


Genmab reported DKK260M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Almirall EUR 30.23M 12.8M Dec/2025
Amarin USD -2.26M 564K Dec/2025
Amgen USD 3.83B 130M Mar/2026
argenx SE USD 394M 22.86M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Bayer EUR 3.53B 2.42B Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Demant DKK 2.09B 224M Dec/2025
Exelixis USD 251.34M 15.43M Mar/2026
Fresenius Medical Care EUR 268M 395M Mar/2026
Genmab DKK 260M 199M Dec/2025
GlaxoSmithKline GBP 2.29B 856M Mar/2026
GN Store Nord DKK -68M 638M Mar/2026
GRIFOLS EUR 249M 26.38M Mar/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Insmed USD -200.28M 49.43M Mar/2026
Lakefront Biotherapeutics EUR -63.7M 844.26M Mar/2026
Lonza CHF 673M 243M Jun/2025
Merck EUR 474M 738M Dec/2025
Novartis USD 4.24B 171M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.94B 239M Mar/2026
UCB EUR 1.29B 571M Dec/2025